Skip to contentZ
Zivo Bioscience, Inc.
Z
ZIVOZivo Bioscience, Inc. Q3 2024 · 10-Q
Revenue$31.50K$31.50K+166.9% vs Q3 2023 Net Income-$2.27M-$2.27MN/M vs Q3 2023 EPS Diluted-$0.67-$0.67no prior Q3 2023 on file Gross Profit$9,450+128.8% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Zivo Bioscience, Inc. · CIK 1101026 · Engraved from SEC EDGAR
Operating Cash Flowderived-$1,085,016N/M Margins · derivedGross margin30.0%−5.0 pt vs Q3 2023
Operating margin-7174.7%+6150.6 pt vs Q3 2023
Net margin-7201.9%+8263.5 pt vs Q3 2023
ended Sep 30, 2024 · filed Nov 14, 2024 · 45 d after period end